Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Weibo Corp (WB) Price & Performance

Heron Therapeutics IncTrade
Weibo CorpTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Weibo Corp — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Weibo Corp trades at $8 (market cap $1.95B). The key difference: Weibo Corp is far larger — about 21.3× Heron Therapeutics Inc's market cap, and Weibo Corp pays a 7.63% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXWB
Market Cap
$91.46M$1.95B
Sector
HealthMedia
52-Week High
$1.96$12.83
52-Week Low
$0.39$7.20
Enterprise Value
$189.36M$1.22B
Dividend Yield
7.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

Weibo Corp

Weibo (WB) trades at $7.995, up 3.16% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows deep value with a P/E of 5.42 and P/B of 0.49, supported by strong profitability including a 21.15% net margin. Recent earnings have slightly missed expectations, but revenue remains stable at $1.76 billion for 2025. News highlights Weibo's cash flow generation and inclusion in value stock lists, though competitive pressures are noted.

The outlook balances significant undervaluation against competitive and execution risks. The market cap of approximately $1.8 billion is below the net balance sheet value, suggesting a margin of safety. Key risks include user engagement challenges from rivals like Douyin and reliance on advertising revenue. Analyst sentiment is mixed but leans positive, with 45% recommending Buy. The stock presents a value opportunity contingent on successful business execution.

Returns comparison

Trailing returns across standard periods

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Weibo Corp

Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.

Read more on WB